No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients

Neoplasma

Volumn 55, Issue 3, 2008, Pages 256-260

  Cho, Y G ^a   Choi, B J ^a   Song, J H ^a   Kim, C J ^a   Cao, Z ^a   Nam, S W ^a   Lee, J Y ^a   Park, W S ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Gastric cancer; Mdm2; p53; Polymorphism; Susceptibility

Indexed keywords

PROTEIN MDM2; RESTRICTION ENDONUCLEASE; MDM2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH ADENOCARCINOMA; GENETIC PREDISPOSITION; GENETICS; KOREA; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; STOMACH NEOPLASMS;

EID: 49049089013     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. SHIN H-R, JUNG K-M, WON Y-J, et al. 139 KCCR-affiliated Hospitals. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Research and Treatment 2004; 36: 103-114.
2. WODARZ A, NUSSE R. Mechanisms of Wnt signaling in development. Ann Rev Cell Dev Biol 1998; 14: 59-88.
3. MOON RT, KOHN AD, DE FERRARI GV, et al. WNT and beta-catenin signaling: disease and therapies. Nat Rev Genet 2004; 5: 691-701.
4. FALETTE N, PAPERIN MP, TREILLEUX I, et al. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998; 58: 1451-1455.
5. MURAKAMI K, FUJIOKA T, OKIMOTO T, et al. Analysis of p53 gene mutations in Helicobacter pylori-associated gastritis mucosa in endoscopic biopsy specimens. Scand J Gastroenterol 1999; 34: 474-477.
6. BOERSMA BJ, HOWE TM, GOODMAN JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006; 98: 911-919. (Pubitemid 44018921)
7. RAYBURN E, ZHANG R, HE J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic marker, and implications for chemotherapy. Curr Cancer Drug Targets 2005; 5: 27-41.
8. LEVAV-COHEN Y, HAUPT S, HAUPT Y. Mdm2 in growth signaling and cancer. Growth Factors 2005; 23: 183-192.
9. ZHANG Y, ZIONG Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001; 292: 1910-1915.
10. MOMAND J, ZAMBETTI GP, OLSON DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
11. MICHAEL D, OREN M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58.
12. BONDS GL, HU W, BOND EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
13. OHMIYA N, TAGUCHI A, MABUCHI N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24: 4434-4440.
14. DHAREL N, KATO N, MUROYAMA R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chromic hepatitis C. Clin Cancer Res 2006; 12: 4867-4871.
15. ALHOPURO P, YLISAUKKO-OJA SK, KOSKINEN WJ, et al. The MDM2 promoter polymorphism SNP309T>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005; 42: 694-698.
16. WALSH CS, MILLER CW, KARLAN BY, et al. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecologic Oncol 2007; 104: 660-664. (Pubitemid 46251415)
17. ZHOU G, ZHAI Y, CUI Y, et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007; 13: 2627-2633.
18. CAMPBELL IG, ECCLES DM, CHOONG DYH. No association of the MDMD2 SNP polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006; 240: 195-197. (Pubitemid 44093819)
19. WILKENING S, HEMMINKI K, RUDNAL P, et al. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol 2007; 157: 375-377. (Pubitemid 47083844)
20. LEE JY, DONG SM, KIM SY, et al. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 1998; 433: 305-309.
21. LEVINE AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
22. GENOGLIO-PREISER CM, WANG J, STEMMERMANN GN, et al. TP53 and gastric carcinoma: A review. Human Mutation 2003; 21: 258-270.
23. HOE YJ, CHO HM, CHIN HM, et al. Gastric cancer susceptibility in the p53 codon 72 polymorphism. J Korean Surg Soc 2005; 69: 24-30.
24. ZHANG ZW, NEWCOMB P, HOLLOWOOD A, et al. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003; 9: 2151-2156.
25. YUASA Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer 2003; 8: 592-600. (Pubitemid 37328831)
26. LAUREN P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification, Acta Pathol Microbiol Scand 1965; 64: 31-49.
27. SOLCIA E, FIOCCA R, LUINETTI O, et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol 1996; 20: S8-22.
28. KODAMA M, FUJIOKA T, MURAKAMI K, et al. Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatolo 2005; 20: 941-946.